Switchpoint Bio Raises $5.3M Pre-Seed to Track Drug Response From Blood

Switchpoint Bio, a biotech startup operating from Helsinki and Cambridge, Massachusetts, has emerged from stealth with $5.3 million in pre-seed financing, according to Tech.eu. The round includes a $5 million investment from Treehouse Delmar Investments.

The company is building an AI-powered epigenomics platform that aims to show how disease and treatment change a patient's biology, using a routine blood draw instead of repeated tissue biopsies.

The Problem It Is Targeting

Modern drugs increasingly act on precise biological mechanisms, but once treatment starts, drug developers have limited tools to see what is actually changing inside a patient. Tissue biopsies are invasive and hard to repeat, which makes it difficult to explain why some patients respond to a therapy and others do not.

"Drug developers need to know not only whether a patient responds, but what biology changed, what persisted and why," said Samuel Myllykangas, PhD, Switchpoint Bio's co-founder and chief executive.

How the Platform Works

Switchpoint Bio uses targeted DNA methylation profiling directly from blood. Methylation patterns act as a chemical record of a cell's state, and the company's AI models read that record to reveal how immune cells shift with disease and treatment.

Because the test runs on a standard blood sample, it can be repeated throughout a clinical trial. That makes it possible to track the biological "switchpoints" the company is named for at the scale drug development requires, supporting biomarker discovery, patient stratification and treatment-response monitoring.

Early Commercial Work

Switchpoint Bio says it is in active discussions with pharmaceutical and biotechnology companies to define its first industry validation programs, with treatment response emerging as a key area of interest. Those programs will be the first proof points for whether blood-based methylation data can deliver decision-grade evidence for drug developers.

The company's U.S. entity, SwitchPoint Bio Holding, filed a Form D in March 2026 reporting $5.27 million in equity sold, consistent with the round now being announced. The filing lists Myllykangas and Jussi Paananen as directors and executives.

Why It Matters

Epigenomics has become a busy area for AI-driven biotech, as companies look for scalable signals that sit between genetics and clinical outcomes. Switchpoint Bio's bet is that the immune system acts as a continuous sensor of what is happening in the body, and that reading it from blood can help pharma companies run smarter trials and understand failures faster.

The size of the round is notable for a pre-seed. Pre-seed therapeutics rounds tracked by VCBacked average about $1.4 million, and Switchpoint Bio's came largely from a single investor, Treehouse Delmar Investments. That concentrated backing gives the company runway to generate data with its own platform and with pharma partners before it needs to approach a broader set of venture investors for a seed or Series A round.

With a well-funded pre-seed and a dual base in the Nordic and Boston biotech hubs, the company now needs to turn pharma conversations into paid validation work.

Source

Tech.eu — Why do some patients respond to drugs and others don't? Switchpoint Bio raises $5.3M to find out